Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Indivior fights off generic challenges but the threat of litigation remains
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
What’s in a p value?
Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…
US regulator sails into treacherous opioid waters
Public criticism fails to derail approval of Acelrx’s opioid painkiller, but not without a lengthy apologia from Scott Gottlieb.
US opioid crisis package nears enactment
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.
The rollercoaster ride continues for China’s cell therapy sector
Companies like Nanjing Legend and Cellular Biomedicine Group continue to attract major financial endorsement from Western big pharma, but the threat of scandal is…
Rebates are dead, long live discounts?
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
Medicare competitive bidding programme begins to take shape
Government document seeks comment on scheme for physician-administered drugs.
